AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$8.56 USD
-0.30 (-3.39%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.56 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANGO 8.56 -0.30(-3.39%)
Will ANGO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANGO
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Other News for ANGO
AngioDynamics (ANGO) Initiates Study on Auryon Atherectomy System
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb ...
AngioDynamics enrolls first patient in Auryon Atherectomy combination study
AngioDynamics (ANGO) Reports Positive Results from PRESERVE Study | ANGO Stock News
AngioDynamics meets primary endpoint in PRESERVE study